American Capital Management Inc. Purchases 3,197 Shares of Insulet Co. (NASDAQ:PODD)

American Capital Management Inc. lifted its stake in Insulet Co. (NASDAQ:PODD - Free Report) by 27.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,800 shares of the medical instruments supplier's stock after buying an additional 3,197 shares during the quarter. American Capital Management Inc.'s holdings in Insulet were worth $3,445,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Blue Trust Inc. boosted its holdings in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 58 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock valued at $36,000 after buying an additional 133 shares during the last quarter. International Assets Investment Management LLC purchased a new position in Insulet during the 2nd quarter valued at approximately $32,000. UMB Bank n.a. increased its stake in Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier's stock worth $37,000 after acquiring an additional 81 shares during the last quarter. Finally, CVA Family Office LLC raised its holdings in shares of Insulet by 138.1% during the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier's stock worth $50,000 after acquiring an additional 145 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts recently weighed in on PODD shares. Sanford C. Bernstein initiated coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an "outperform" rating and a $300.00 target price for the company. Raymond James lifted their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a research note on Monday, October 14th. Canaccord Genuity Group increased their price target on shares of Insulet from $236.00 to $269.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. Morgan Stanley boosted their price objective on Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research note on Monday, November 11th. Finally, Barclays raised their price objective on Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, Insulet currently has an average rating of "Moderate Buy" and an average target price of $253.27.

Insulet Trading Down 0.1 %

Shares of NASDAQ PODD traded down $0.14 during mid-day trading on Friday, reaching $266.78. The company had a trading volume of 250,910 shares, compared to its average volume of 625,543. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40. The business's 50-day moving average is $244.40 and its 200-day moving average is $214.14. The stock has a market cap of $18.71 billion, a price-to-earnings ratio of 45.68, a price-to-earnings-growth ratio of 4.08 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.